Biodistribution and individual dosimetry of I-131-labeled Rituximab in relapsed non-Hodgkin's lymphoma

被引：0
|
作者：
Scheidhauer, K
Wolf, I
von Schilling, C
Schmidt, B
Baumgartl, H
Reidel, G
Peschel, C
Schwaiger, M
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, D-8000 Munich, Germany
[2] Tech Univ Munich, Med Klin 3, D-8000 Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 2001年 / 28卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OS79
引用
收藏
页码：981 / 981
页数：1
相关论文
共 50 条
  • [21] A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma
    Bond, David A.
    Huang, Ying
    Christian, Beth A.
    Jaglowski, Samantha
    Benson, Don
    Alinari, Lapo
    Baiocchi, Robert A.
    Cohen, Jonathon B.
    Blum, Kristie A.
    Maddocks, Kami J.
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1750 - 1753
  • [22] Tandem myeloablative 131I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients
    Deshayes, Emmanuel
    Kraeber-Bodere, Francoise
    Vuillez, Jean-Philippe
    Bardies, Manuel
    Teulon, Isabelle
    Pouget, Jean-Pierre
    IMMUNOTHERAPY, 2013, 5 (12) : 1283 - 1286
  • [23] Human-mouse chimeric 131I-labeled anti-CD20 monoclonal antibody (MAB) in relapsed non-Hodgkin's lymphoma (NHL):: Dosimetry and radioimmunotherapy (RIT).
    Scheidhauer, K
    Baumgartl, HJ
    von Schilling, C
    Schmidt, B
    Wolf, I
    Reidel, G
    Peschel, C
    Schwaiger, M
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 268P - 268P
  • [24] Tumor targeting, dosimetry and clinical response data for lymphorad-131 (LR131; iodine I-131 labeled B-lymphocyte stimulator) in patients with relapsed/refractory non-Hodgkin's lymphoma.
    Belch, A
    McEwan, A
    Hewitt, J
    Riauka, T
    Stabin, M
    Brill, A
    Gallant, G
    Blake, L
    Klein, J
    BLOOD, 2004, 104 (11) : 214A - 215A
  • [25] Safety and Efficacy of I(131) Tositumomab in the Treatment of non-Hodgkin's Lymphoma
    Illidge, Tim
    Ivanov, Andrei
    Du, Yong
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 621 - 631
  • [26] The therapeutic use of rituximab in non-Hodgkin's lymphoma
    Marcus, Robert
    Hagenbeek, Anton
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 78 : 5 - 14
  • [27] Rituximab therapy for indolent non-Hodgkin's lymphoma
    Hagenbeek, A
    Czuczman, MS
    Ghielmini, M
    Herold, M
    Kimby, E
    Solal-Céligny, P
    Unterhalt, M
    ANTI-CANCER DRUGS, 2002, 13 : S11 - S17
  • [28] Rituximab induced hypoglycemia in non-Hodgkin's lymphoma
    Hussain B.M.
    Geetha N.
    Lali V.
    Pandey M.
    World Journal of Surgical Oncology, 4 (1)
  • [29] Rituximab: An innovative therapy for non-Hodgkin's lymphoma
    Wood, AM
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2001, 58 (03) : 215 - 229
  • [30] Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma
    不详
    EUROPEAN JOURNAL OF CANCER CARE, 2003, 12 (04) : 306 - 307
12345